Biomarker: F006-IgE Barley

Overview

F006-IgE Barley measures immunoglobulin E (IgE) antibodies in blood that bind to barley (Hordeum vulgare) allergens. IgE is involved in immediate-type allergic reactions, including urticaria, angioedema, gastrointestinal symptoms, respiratory symptoms, and anaphylaxis. A high result indicates sensitization to barley but does not by itself confirm clinical barley allergy or predict reaction severity. The test is clinically useful when interpreted with the patient’s reaction history and, when necessary, skin testing or a medically supervised oral food challenge.

Clinical Use Cases

Supports evaluation of suspected IgE-mediated reactions after eating barley or barley-containing foods.
Assesses sensitization in patients with suspected cereal-grain allergy.
Helps evaluate possible cross-sensitization or cross-reactivity among barley, wheat, and rye.
Provides an alternative to skin-prick testing when antihistamine use, extensive eczema, dermatographism, or concern about provoking a reaction limits skin testing.
May support evaluation of rare occupational or food-induced respiratory reactions associated with barley flour exposure.
May be used in clinical research investigating barley allergy and cereal-grain allergenicity.

Specimen Types

Venous blood serum, the usual specimen for quantitative barley-specific IgE testing.
Plasma may be accepted by some laboratory methods, according to the assay protocol.

Measurement Methods

In vitro allergen-specific IgE immunoassay using an extract of barley allergens.
Fluorescence enzyme immunoassay, including CAP-based assays.
Chemiluminescent immunoassay.
Enzyme-linked immunosorbent assay.
Radioallergosorbent testing is an older method; modern fluorescence- or chemiluminescence-based assays are generally preferred.
Skin-prick testing with barley extract is a complementary in vivo method, but it measures cutaneous reactivity rather than serum F006-IgE directly.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergy blood test.
Patients should report all medications and supplements to the ordering clinician.
Antihistamines generally do not interfere with serum-specific IgE testing, although they can affect skin-prick testing. Medication changes should be made only under clinical guidance.
Total IgE concentration, assay platform, allergen extract composition, and laboratory calibration can influence measured values.
Results may vary between assay methods and should be interpreted using the reporting laboratory’s reference ranges and units.
A positive result indicates sensitization, not necessarily symptomatic allergy.
The concentration of barley-specific IgE does not reliably predict the severity of a future reaction.
Cross-reactive proteins in wheat, barley, and rye may produce positive results without equivalent clinical reactions to each grain.
Testing should be targeted to a relevant clinical history because broad food-allergy panels can identify sensitization that is not clinically meaningful.